{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:17:51Z","timestamp":1790011071504,"version":"4.0.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11845-021-02885-9","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:04:35Z","timestamp":1642205075000},"page":"2569-2577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dyslipidaemia management in the cardiac rehabilitation clinic of a tertiary referral centre: analysis of the impact of new ESC guidance on LDL-C target achievement"],"prefix":"10.1007","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2593-6940","authenticated-orcid":false,"given":"Conor","family":"McCaughey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Kerins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,15]]},"reference":[{"key":"2885_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"key":"2885_CR2","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713\u20131722. https:\/\/doi.org\/10.1056\/NEJMoa1615664","journal-title":"N Engl J Med"},{"key":"2885_CR3","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M et al (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379:2097\u20132107. https:\/\/doi.org\/10.1056\/NEJMoa1801174","journal-title":"N Engl J Med"},{"key":"2885_CR4","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1093\/eurheartj\/ehn478","volume":"29","author":"RH Mehta","year":"2008","unstructured":"Mehta RH, Bhatt DL, Steg PhG et al (2008) Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry. Eur Heart J 29:3052\u20133060. https:\/\/doi.org\/10.1093\/eurheartj\/ehn478","journal-title":"Eur Heart J"},{"key":"2885_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/1741826711400545","volume":"19","author":"AK Gitt","year":"2012","unstructured":"Gitt AK, Drexel H, Feely J et al (2012) Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol 19:221\u2013230. https:\/\/doi.org\/10.1177\/1741826711400545","journal-title":"Eur J Prev Cardiol"},{"key":"2885_CR6","first-page":"820","volume":"83","author":"S Mendis","year":"2005","unstructured":"Mendis S, Abegunde D, Yusuf S et al (2005) WHO study on Prevention of recurrences of myocardial infarction and stroke (WHO-PREMISE). Bull World Health Organ 83:820\u2013829","journal-title":"Bull World Health Organ"},{"key":"2885_CR7","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1177\/2047487318825350","volume":"26","author":"K Kotseva","year":"2019","unstructured":"Kotseva K, De Backer G, De Bacquer D et al (2019) Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol 26:824\u2013835. https:\/\/doi.org\/10.1177\/2047487318825350","journal-title":"Eur J Prev Cardiol"},{"key":"2885_CR8","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM et al (2021) EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol 28:1279\u20131289. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa047","journal-title":"Eur J Prev Cardiol"},{"key":"2885_CR9","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1177\/2047487315569401","volume":"23","author":"K Kotseva","year":"2016","unstructured":"Kotseva K, Wood D, De Bacquer D et al (2016) EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 23:636\u2013648. https:\/\/doi.org\/10.1177\/2047487315569401","journal-title":"Eur J Prev Cardiol"},{"key":"2885_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ijcard.2017.10.080","volume":"253","author":"MC Stam-Slob","year":"2018","unstructured":"Stam-Slob MC, van der Graaf Y, de Boer A et al (2018) Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease. Int J Cardiol 253:148\u2013154. https:\/\/doi.org\/10.1016\/j.ijcard.2017.10.080","journal-title":"Int J Cardiol"},{"key":"2885_CR11","unstructured":"HSE Criteria for the reimbursement of PCSK9i in Ireland (2020). In HSE.ie. https:\/\/www.hse.ie\/eng\/about\/who\/cspd\/ncps\/medicines-management\/pcsk9-inhibitors\/pcsk9-inhibitors.html. Accessed 29 Nov 2021"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-021-02885-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-021-02885-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-021-02885-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T10:25:10Z","timestamp":1744194310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-021-02885-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2885"],"URL":"https:\/\/doi.org\/10.1007\/s11845-021-02885-9","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,15]]},"assertion":[{"value":"24 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The requirement for ethical review was waived by the St James Hospital Institutional Review Board (Research and Innovation approval number ref: 6562) due to the retrospective nature of the study and the processing of data in line with routine quality and improvement. The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}